Drawing for INNUREX

USPTO serial 78378648

INNUREX

Reviewed by CopyMark Law Group

Reg. 3431115Status 710
Filing date
Status date
Registration date
May 20, 2008
Examiner
ALI, STEPHANIE MARIE
Law office
POST REGISTRATION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with INNUREX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Purvi J. Patel

Purvi J. Patel Haynes and Boone, LLP2323 Victory Avenue, Suite 700Dallas, TX 75219-7673UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical and biochemical products for use in gene delivery technology, enzymes and chemicals for in vitro use in laboratories and for analysis in gene delivery technology, enzymes and chemicals for in vitro use in laboratories and for analysis in gene delivery technology, micro-organisms, cell cultures, plasmids and cultures of micro-organisms, deoxyribonucleic acid sequences, cloning vehicles and recombinant deoxyribonucleic variations thereof, all for in vivo use in gene delivery technology and catalysts for gene delivery technology in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and diseaseSECTION 8 - CANCELLED—
005Gene therapy and prophylaxis products, pharmaceutical substances and preparations for use in the medical industry, namely, vaccines, enzymes and enzyme preparations, anti-apoptopic and angiostatic/angiogenic molecules, retroviral vector and retroviral vector manufacturing preparations, all for use in gene delivery technologies in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; vector production technologies and neurogenomics products in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; Chemical products for use in medical science for the treatment of diseases of the eye, vascular and neo-vascularisition disorders, single gene disorders, cancer, diseases of the nervous system, inflammatory and auto-immune diseases, blood disorders, vascular disorders and disorders arising from inappropriate vascularisation *and injuries of the nervous, system all* in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and disease; pharmaceutical and biochemical preparations for the treatment of damaged nerves and spinal injuries and for the induction of nerve re-growth; medical instruments and apparatus for the administration of gene and antibody-based therapy and prophylactics, preparations and substances, namely, pre-filled vials, syringes and injectors for medical purposes, all in the fields of disease and injury of the nervous system, including spinal cord injury and disease and peripheral nerve injury and diseaseSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 26, 2014C8..CANCELLED SEC. 8 (6-YR)—
Jun 1, 2009COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Jan 6, 2009PLGLASSIGNED TO PARALEGAL—
Dec 17, 2008TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 17, 2008TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 9, 2008ES7RTEAS SECTION 7 REQUEST RECEIVED—
Sep 15, 2008COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Sep 15, 2008PLGLASSIGNED TO PARALEGAL—
May 20, 2008R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 16, 2008TMBNTTAB RELEASE CASE TO TRADEMARKS—
Apr 16, 2008OP.TOPPOSITION TERMINATED NO. 999999—
Apr 16, 2008OP.DOPPOSITION DISMISSED NO. 999999—
Mar 4, 2008MAILPAPER RECEIVED—
Mar 9, 2006OP.IOPPOSITION INSTITUTED NO. 999999—
Dec 8, 2005ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Nov 8, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 19, 2005NPUBNOTICE OF PUBLICATION—
Sep 22, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 16, 2005ALIEASSIGNED TO LIE—
Sep 13, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 13, 2005XAECEXAMINER'S AMENDMENT ENTERED—
Sep 13, 2005CNEAEXAMINERS AMENDMENT MAILED—
Sep 13, 2005CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 9, 2005ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Aug 22, 2005CWBPWITHDRAWN BEFORE PUBLICATION—
May 24, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 20, 2005ALIEASSIGNED TO LIE—
May 17, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 23, 2005TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 16, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 16, 2005TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 22, 2004CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 21, 2004CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 20, 2004DOCKASSIGNED TO EXAMINER—
Mar 19, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance